Electrocardiographic effects of methylphenidate overdose

Clinical Toxicology

Volumn 48, Issue 4, 2010, Pages 342-346

  Hill, S L ^a   El Khayat, R H ^a   Sandilands, E A ^b   Thomas, S H L ^a,c  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Arrhythmias; ECG changes; Overdose; Toxicology

Indexed keywords

METHYLPHENIDATE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ANXIETY; ARTICLE; CLINICAL ARTICLE; CONSCIOUSNESS LEVEL; CONTROLLED STUDY; DRUG OVERDOSE; ELECTROCARDIOGRAPHY; FEMALE; GLASGOW COMA SCALE; HEART PALPITATION; HEART RATE; HEART REPOLARIZATION; HEMODYNAMICS; HUMAN; MALE; MYDRIASIS; QT INTERVAL; QT PROLONGATION; THORAX PAIN; VOMITING;

ADOLESCENT; ADULT; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; MIDDLE AGED; OVERDOSE; YOUNG ADULT;

EID: 77952917125     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563651003720234     Document Type: Article

References (16)

1. Scharman EJ, Erdman AR, Cobaugh DJ, Olson KR, Woolf AD, Caravati EM, Chyka PA, Booze LL, Manoguerra AS, Nelson LS, Christianson G, Troutman WG. Methylphenidate poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol 2007; 45:737-752. (Pubitemid 350214322)
2. US Food and Drug Administration, Pediatric Advisory Committee. Briefing information. 30 June 2005. http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4152b2.htm. Accessed 25 November 2009.
3. Medicines and Healthcare Products Regulatory Agency. Summary of the meeting of the Pharmacovigilance Expert Advisory Group held on 7 November 2007. http://www.mhra.gov.uk/home/groups/l-cs-el/documents/committeedocument/ con2033716.pdf. Accessed 25 November 2009.
4. US Food and Drug Administration. Drug Safety and Risk Management Advisory Committee Meeting. 9-10 February 2006. http://www.fda.gov/ ohrms/DOCKETS/ac/06/ transcripts/2006-4202t1.pdf. Accessed 25 November 2009.
5. Gould MS, Walsh BT, Munfakh JL, Kleinman M, Duan N, Olfson M, Greenhill L, Cooper T. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166:992-1001.
6. European Medicines Agency. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. http://www.emea.europa.eu/pdfs/human/ich/000204en.pdf. Accessed 25 November 2009.
7. Wakamatsu A, Nomura S, Tate Y, Shimizu S, Harada Y. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods 2009; 59:128-134.
8. Ilgenli TF, Congologlu A, Ozturk C, Turkbay T, Akpinar O, Kilicaslan F. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Adv Ther 2007; 24:182-188.
9. Pekdemir H, Toros F, Çamsari A, Çicek D, Yurtda1 M, Parmaksiz T, Katircibali T, The effect of methylphenidate on cardiovascular functions in the treatment of attention deficit hyperactivity disorder. Çocuk ve Gençlik Ruh Sagligi Dergisi (J Child Adolesc Ment Health) 2003; 10:9-16.
10. Krantz MJ, Kutinsky IB, Robertson AD, Mehler PS. Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes. Pharmacotherapy 2003; 23:802-805.
11. Desai M, Li L, Zeruesenay D, Malik M, Flockhart D. Variability of heart rate correction methods for the QT interval. Br J Clin Pharmacol 2003; 55:511-517. (Pubitemid 36783190)
12. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QT interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048-1052.
13. Isbister GK, Friberg LE, Duffull SB. Application of pharmacokineticpharmacodynamic modelling in management of QT abnormalities after citalopram overdose. Intensive Care Med 2006; 32:1060-1065.
14. Foley R, Mrvos R, Krenzelok EP. A profile of methylphenidate exposures. Clin Toxicol 2000; 38:625-630.
15. Klein-Schwartz W. Pediatric methylphenidate exposures: 7-year experience of poison centers in the United States. Clin Pediatr (Phila) 2003; 42:159-164.
16. Klein-Schwartz W, McGrath J. Poison centers' experience with methylphenidate abuse in pre-teens and adolescents. J Am Acad Child Adolesc Psychiatry 2003; 42:288-294. (Pubitemid 39592084)